Nevertheless, Sam68 targeting significantly reduced the cell viability of tamoxifen-resistant ER+ BC cells treated with dinaciclib, suggesting that this combination may result in a potential effective therapy. This evidence concerns the gene KHDRBS1 and breast cancer.